Inuvo Past Earnings Performance

Past criteria checks 0/6

Inuvo's earnings have been declining at an average annual rate of -15%, while the Software industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 9.1% per year.

Key information

-15.0%

Earnings growth rate

8.7%

EPS growth rate

Software Industry Growth14.9%
Revenue growth rate9.1%
Return on equity-67.0%
Net Margin-10.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Inuvo makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:CD5N Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2478-8760
30 Jun 2481-7780
31 Mar 2479-9790
31 Dec 2374-10740
30 Sep 2370-12690
30 Jun 2363-15590
31 Mar 2369-14580
31 Dec 2276-13580
30 Sep 2278-10550
30 Jun 2278-8550
31 Mar 2268-8520
31 Dec 2160-8520
30 Sep 2153-7520
30 Jun 2145-8470
31 Mar 2140-7420
31 Dec 2045-7440
30 Sep 2050-7460
30 Jun 2055-4460
31 Mar 2061-5490
31 Dec 1962-4460
30 Sep 1960-6430
30 Jun 1963-8440
31 Mar 1968-7470
31 Dec 1873-6490
30 Sep 1880-3500
30 Jun 1884-2500
31 Mar 1883-3490
31 Dec 1780-3470
30 Sep 1775-4460
30 Jun 1773-4470
31 Mar 1770-3480
31 Dec 1672-1510
30 Sep 16730550
30 Jun 16751550
31 Mar 16762520
31 Dec 15702450
30 Sep 15652370
30 Jun 15592310
31 Mar 15532280
31 Dec 14502270
30 Sep 14461240
30 Jun 14471230
31 Mar 14491230
31 Dec 13550260

Quality Earnings: CD5N is currently unprofitable.

Growing Profit Margin: CD5N is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CD5N is unprofitable, and losses have increased over the past 5 years at a rate of 15% per year.

Accelerating Growth: Unable to compare CD5N's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CD5N is unprofitable, making it difficult to compare its past year earnings growth to the Software industry (10.6%).


Return on Equity

High ROE: CD5N has a negative Return on Equity (-66.96%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies